Sadly, Sue Webb passed away this week. She was only in having physio last Friday. I do not have any further details, I am sure Chris will give me a call soon. Just thought I should let you know. It’s very sad news.
Posts By: Karen Jones
Can you help?
Does anyone have a spare wheelchair, we need a good lightweight one at the centre?
Membership 2020 and donations
The donation rates are remaining the same for 2020 even though we have not had a good year with regards to fundraising income. We have had no sponsored events at all in 2019. If you or anyone you knows is/or can do a sponsored event for us please do encourage it. If you have any fundraising… Read more »
Thinking of something to do this Sunday ….. visit the Christmas Craft Fair at Harwell Village Hall…..
Do you shop online at Amazon?
Single Dose of CD45-ADC Resets the Immune System, Delays the Onset of MS in Mice
From Multiple Sclerosis News Today A single dose of CD45-ADC, an investigational targeted therapy being developed to treat different types of autoimmune diseases, is enough to reset the normal function of the body’s immune system in a mouse model of multiple sclerosis (MS), and to delay onset of the disease. Those findings were presented earlier… Read more »
DWP breached advertising standards
Source MS Society: The Advertising Standards Authority (ASA) has upheld our complaint against the Government’s Universal Credit adverts. Formal investigation In June, as part of the Disability Benefits Consortium (DBC), we submitted a complaint to the ASA about the DWP’s advertising campaign in the Metro newspaper. The ads claimed to be a “myth buster” on Universal Credit. But… Read more »
Sativex cost-effective in final NICE guideline on cannabis-based medicines
Source MS Trust: Sativex is a cost-effective treatment for people with MS spasticity according to new guidance published today by NICE(link is external). This reverses the decision made in draft guidance published earlier this year. The guideline recommends that, providing the local NHS health authority is willing to pay for continued treatment, a 4-week trial of Sativex can be offered to people… Read more »
European drug regulator recommends restricted use of Lemtrada
Source MS Trust: Lemtrada (alemtuzumab) should be restricted to people with highly active relapsing-remitting MS according to a review carried out by the European Medicines Agency’s (EMA) drug safety committee. Highly active relapsing-remitting MS covers people who continue to have relapses despite taking at least one disease-modifying drug (DMD) or if MS is worsening rapidly with at least two… Read more »
Cannabis-based medicines: Two drugs approved for NHS
Source BBC: Two cannabis-based medicines, used to treat epilepsy and multiple sclerosis, have been approved for use by the NHS in England. It follows new guidelines from the drugs advisory body NICE, which looked at products for several conditions. Charities have welcomed the move, although some campaigners who have been fighting for access to the drugs… Read more »
